| Zhong15) (2019) | 1) 80 (46/34)2) 80 (45/35) | 1)13.39±3.552)13.27±3.22 | 1)68.92±5.162)68.38±5.77 | BYHW' + Xueshuantong 1C Tid | Xueshuantong1C Tid | 3months | ① effective rate② visual acuity(n,%) | ① (I) 92.50% (C) 73.75% (P<0.05)② 1. visual improvement (I) 36(45.00) (C) 18(22.50) (P<0.05) 2. vision maintenance (I) 38(47.50) (C) 44(55.00) (P>0.05) 3. decreased vision (I) 8(10.00)(C) 19(23.75) (P<0.05) | NR |
| Ai16) (2018) | 1) 40 (26/15)2) 40 (27/13) | 1)12.75±3.042)13.04±3.11 | 1)61.30±6.722)60.42±7.03 | BYHW(C)+WM (Alprostadil 10㎍ + N/S 10㎖ IV injection Bid) | WM(Alprostadil 10㎍ + N/S 10㎖ IV injection Bid) | 8weeks | ① effective rate② retinal hemodynamics1. EDV(㎝/s)2. PSV(㎝/s)3. CRV(㎝/s)4. Vm(㎝/s)5. RI6. PI③ serum cytokine levels1. Hcy(pg/㎖)2. TGF-β1(ng/L)3. ICAM-1(㎍/L)4. TNF-α(ng/L) | ① (I) 92.5 (C) 72.5② 1. EDV(㎝/s) (I) 4.28±0.56 (C) 3.62±0.40 (P<0.05) 2. PSV(㎝/s) (I) 12.04±1.32 (C) 9.13±1.25 (P<0.05) 3. CRV(㎝/s) (I) 6.11±0.73 (C) 7.58±0.91 (P<0.05) 4. Vm(㎝/s) (I) 7.82±0.87 (C) 6.10±0.72 (P<0.05) 5. RI (I) 0.53±0.08 (C) 0.66±0.12 (P<0.05) 6. PI (I) 1.24±0.10 (C) 1.53±0.22 (P<0.05)③ 1. Hcy(pg/㎖) (I) 80.76±7.27 (C) 106.25±10.64 (P<0.05) 2. TGF-β1(ng/L) (I) 178.93±19.60 (C) 264.41±23.54 (P<0.05) 3. ICAM-1(㎍/L) (I) 92.27±12.39 (C) 135.46±16.53 (P<0.05) 4. TNF-α(ng/L) (I) 53.62±7.75 (C) 87.81±10.22 (P<0.05) | NR |
| Tang17) (2013) | 1) 64 (40/24)2) 60 (24/36) | NR | 63.1±3.2 | BYHW' 1Pk Bid + WM(metormin 500-750㎎ Bid or Tid, iodized lecithin 9㎎ Tid) | WM(metormin 500-750㎎ Bid or Tid, iodized lecithin 9㎎ Tid) | 1month | ① effective rate | ① (I) 89.06% (C) 67.76% (P<0.01) | (I) 0(C) 0 |
| Tang18) (2011) | 1) 35 (19/16)2) 35 (17/18) | 1)6.712)6.65 | 1)57.232)56.91 | BYHW' Bid | WM(dobesilate calcium 500㎎ 1C Tid) | 8weeks | ① effective rate② FBG(m㏖/L)③ 2hPG(m㏖/L)④ HbA1c(%)⑤ ET-1(ng/L)⑥ NO(μ㏖/L) | ① (I) 85.9% (C) 67.7% (P<0.05)② (I) 6.90±0.56 (C)7.02±0.89 (P<0.01)③ (I) 8.97±0.87 (C) 9.36±0.72 (P<0.01)④ (I) 7.36±0.59 (C) 7.69±0.75 (P<0.01)⑤ (I) 77.22±17.95 (C) 97.01±13.75 (P<0.05)⑥ (I) 41.53±7.12 (C) 39.18±6.08 (P<0.05) | NR |
| Li19) (2007) | 1) 30 (13/17)2) 30 (16/14) | 1)7.402)7.70 | 1)59.372)59.97 | BYHW' Qd | WM(aspirin enteric-coated Tablet 100㎎ 1T Qd ) | 8weeks | ① FBG(m㏖/L)② 2hPG(m㏖/L)③ HbA1c(%)④ hemorheology index1. Whole Blood Viscosity(High Shear)(mpa·s)2. Whole Blood Viscosity(Low Shear)(mpa·s)3. plasma viscosity(mpa·s)4. Hct5. ESR(㎜/1hr)6. erythrocyte aggregation index | ① (I) 5.16±0.46 (C) 5.15±0.37 (P>0.05)② (I) 6.73±0.86 (C) 6.77±0.80 (P>0.05)③ (I) 6.43±0.78 (C) 6.18±0.59 (P>0.05)④ 1. (I) 4.09±0.56 (C) 4.69±0.6 (P<0.01) 2. (I) 9.69±0.88 (C) 0.43±0.74 (P<0.01) 3. (I) 1.52±0.10 (C) 1.69±0.15 (P<0.05) 4. (I) 0.42±0.02 (C) 0.46±0.03 (P<0.01) 5. (I) 7.67±3.21 (C) 8.33±4.14 6. (I) 8.17±0.85 (C) 8.65±0.8 (P<0.05) | NR |
| Lu20) (2020) | 1) 40 (22/18)2) 40 (23/17) | 1)12.18±2.242)12.05±2.16 | 1)63.28±7.542)63.52±7.63 | BYHW' 1Pk Bid + WM(laser photocoagulation) | WM(laser photocoagulation) | 1month | ① effective rate② visual acuity(n,%)③ ApoB(g/L)④ LP-a(㎎/L)⑤ TRF(g/L) | ① (I) 97.50% (C) 80.00% (P<0.05)② 1. visual improvement (I) 22(34.38)(C) 10(15.87) (P<0.05) 2. unchanged (I) 39(60.94) (C) 40(63.49) 3. decreased vision (I) 3(4.68) (C) 13(20.64) (P<0.05)③ (I) 0.91±0.18 (C) 1.25±0.37 (P<0.05)④ (I) 115.36±12.16 (C) 162.05±17.08 (P<0.05)⑤ (I) 2.85±0.31 (C) 2.40±0.25 (P<0.05) | NR |
| Yang21) (2019) | 1) 40 (NR/NR)2) 40 (NR/NR) | 1)9.87±1.462)10.22±1.50 | 1)50.35±9.062)48.66±8.82 | BYHW' 1Pk Qd + WM(dobesilate calcium 500㎎ 2C Tid) | WM(dobesilate calcium 500㎎ 2C Tid) | 2months | ① effective rate② visual acuity③ FBG(m㏖/L) | ① (I) 90.0% (C) 75.0% (P<0.05)② (I) 0.55±0.14 (C) 0.42±0.12 (P<0.05)③ (I) 7.01±1.12 (C) 7.22±1.45 (P<0.05) | NR |
| Qu22) (2009) | 1) 32 (20/12)2) 30 (12/18) | NR | 65.2 | BYHW' 1Pk Bid + WM(gliclazide 160-240㎎ Tid, lecithin 9㎎ Tid) | WM(gliclazide 160-240㎎ Tid, lecithin 9㎎ Tid) | 1month | ① effective rate | ① (I) 90.6% (C) 76.7% (P<0.05) | NR |